Literature DB >> 27359073

Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases.

E D Batu1, A Erden2, E Seyhoğlu3, L Kilic2, Y Büyükasık4, O Karadag2, Y Bilginer1, S A Bilgen2, A Akdogan2, S Kiraz2, A I Ertenli2, S Özen1, U Kalyoncu2.   

Abstract

OBJECTIVES: Reactive haemophagocytic syndrome (RHS) is a hyperinflammatory disorder often occurring in the background of several disorders such as infections, malignancies, and rheumatic diseases. Recently, a score known as the HScore was developed for the diagnosis of RHS. In the original study, most of the patients had underlying haematological malignancy or infection and the best cut-off value for the HScore was 169 (sensitivity 93%; specificity 86%). In this study we aimed to analyse the performance of the HScore in rheumatic disease-related RHS.
METHOD: The patients with rheumatic disorders evaluated in the Departments of Rheumatology and Paediatric Rheumatology at Hacettepe University, Ankara, Turkey between 2002 and 2014 were reviewed retrospectively. The first group (n = 30) consisted of patients with RHS; the control group (n = 64) included patients with active rheumatic diseases without RHS.
RESULTS: In the RHS group, 14 (46.7%) had adult-onset Still's disease (AOSD), 10 (33.3%) systemic juvenile idiopathic arthritis (SJIA), and six (20%) systemic lupus erythematosus (SLE). The control group (n = 64) consisted of 32 (50%) AOSD, 13 (20.3%) SJIA, and 19 (29.7%) SLE patients. Applying the HScore to the RHS patients, the best cut-off value was 190.5 with a sensitivity of 96.7% and specificity of 98.4%. When we excluded the patients from the control group who had not had bone marrow aspiration (n = 23), the same cut-off (190.5) performed best (sensitivity 96.7%; specificity 97.6%). Applying the 2004 haemophagocytic lymphohistiocytosis (HLH-2004) criteria gave a sensitivity of 56.6% and a specificity of 100% in the whole study group.
CONCLUSIONS: In our study, a cut-off value for the HScore different from the original study performed better. Further studies are warranted to determine optimum cut-off values in different studies.

Entities:  

Mesh:

Year:  2016        PMID: 27359073     DOI: 10.3109/03009742.2016.1167951

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  14 in total

1.  Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients.

Authors:  Ammouri Wafa; Harmouche Hicham; Radi Naoufal; Khibri Hajar; Razine Rachid; Benkirane Souad; Maamar Mouna; Mezalek Tazi Zoubida; Adnaoui Mohamed
Journal:  Clin Rheumatol       Date:  2022-02-18       Impact factor: 2.980

2.  Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study.

Authors:  Piero Ruscitti; Ilenia Di Cola; Onorina Berardicurti; Alessandro Conforti; Daniela Iacono; Ilenia Pantano; Gelsomina Rozza; Silvia Rossi; Ludovico De Stefano; Silvia Balduzzi; Antonio Vitale; Francesco Caso; Luisa Costa; Marcella Prete; Luca Navarini; Fabiola Atzeni; Giuliana Guggino; Federico Perosa; Luca Cantarini; Bruno Frediani; Carlomaurizio Montecucco; Francesco Ciccia; Roberto Giacomelli; Paola Cipriani
Journal:  Clin Rheumatol       Date:  2021-10-11       Impact factor: 3.650

3.  Performances of the "MS-score" And "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.

Authors:  Erdal Sag; Armagan Keskin; Erdal Atalay; Selcan Demir; Muserref Kasap Cuceoglu; Ummusen Kaya Akca; Ezgi Deniz Batu; Yelda Bilginer; Seza Ozen
Journal:  Rheumatol Int       Date:  2020-11-19       Impact factor: 2.631

4.  Combination Immunosuppressive Therapy Including Rituximab for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Adult-Onset Still's Disease.

Authors:  Eva Johanna Schäfer; Wolfram Jung; Peter Korsten
Journal:  Case Rep Rheumatol       Date:  2016-11-28

5.  Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers.

Authors:  Piero Ruscitti; Paola Cipriani; Francesco Masedu; Daniela Iacono; Francesco Ciccia; Vasiliki Liakouli; Giuliana Guggino; Francesco Carubbi; Onorina Berardicurti; Paola Di Benedetto; Marco Valenti; Giovanni Triolo; Gabriele Valentini; Roberto Giacomelli
Journal:  BMC Med       Date:  2016-12-01       Impact factor: 8.775

6.  A reminder of the place of morphology and the H-score in the diagnosis of hemophagocytic lymphohistiocytosis (HLH).

Authors:  Julien Favresse; Benjamin Lardinois; Bernard Chatelain; François Mullier; Hugues Jacqmin
Journal:  Clin Case Rep       Date:  2018-02-06

Review 7.  Macrophage activation syndrome associated with griscelli syndrome type 2: case report and review of literature.

Authors:  Zakia Sefsafi; Brahim El Hasbaoui; Amina Kili; Aomar Agadr; Mohammed Khattab
Journal:  Pan Afr Med J       Date:  2018-01-25

8.  Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients.

Authors:  Piero Ruscitti; Onorina Berardicurti; Daniela Iacono; Ilenia Pantano; Vasiliki Liakouli; Francesco Caso; Giacomo Emmi; Rosa Daniela Grembiale; Francesco Paolo Cantatore; Fabiola Atzeni; Federico Perosa; Raffaele Scarpa; Giuliana Guggino; Francesco Ciccia; Antonio Barile; Paola Cipriani; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2020-06-22       Impact factor: 5.156

9.  Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a small child: A case report.

Authors:  Maria Oana Mărginean; Eniko Molnar; Mihaela Ioana Chinceşan
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

10.  Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations.

Authors:  Piero Ruscitti; Paola Di Benedetto; Onorina Berardicurti; Noemi Panzera; Nicolò Grazia; Anna Rita Lizzi; Paola Cipriani; Yehuda Shoenfeld; Roberto Giacomelli
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.